Century Therapeutics (IPSC) Competitors $0.59 +0.01 (+2.18%) As of 12:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPSC vs. NMRA, FDMT, NLTX, EPRX, VTYX, OGI, SLS, YMAB, ALMS, and CTMXShould you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Neumora Therapeutics (NMRA), 4D Molecular Therapeutics (FDMT), Neoleukin Therapeutics (NLTX), Eupraxia Pharmaceuticals (EPRX), Ventyx Biosciences (VTYX), Organigram Global (OGI), SELLAS Life Sciences Group (SLS), Y-mAbs Therapeutics (YMAB), Alumis (ALMS), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry. Century Therapeutics vs. Its Competitors Neumora Therapeutics 4D Molecular Therapeutics Neoleukin Therapeutics Eupraxia Pharmaceuticals Ventyx Biosciences Organigram Global SELLAS Life Sciences Group Y-mAbs Therapeutics Alumis CytomX Therapeutics Century Therapeutics (NASDAQ:IPSC) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends. Which has more risk & volatility, IPSC or NMRA? Century Therapeutics has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.75, meaning that its share price is 175% more volatile than the S&P 500. Do insiders and institutionals have more ownership in IPSC or NMRA? 50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 5.0% of Century Therapeutics shares are held by insiders. Comparatively, 26.8% of Neumora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, IPSC or NMRA? Century Therapeutics has higher revenue and earnings than Neumora Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentury Therapeutics$6.59M7.73-$126.57M-$0.29-2.04Neumora TherapeuticsN/AN/A-$243.79M-$1.61-0.85 Does the media favor IPSC or NMRA? In the previous week, Neumora Therapeutics had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 4 mentions for Neumora Therapeutics and 2 mentions for Century Therapeutics. Neumora Therapeutics' average media sentiment score of 1.00 beat Century Therapeutics' score of 0.37 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Neumora Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend IPSC or NMRA? Century Therapeutics currently has a consensus price target of $4.20, indicating a potential upside of 610.66%. Neumora Therapeutics has a consensus price target of $7.14, indicating a potential upside of 423.29%. Given Century Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Century Therapeutics is more favorable than Neumora Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Century Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22 Is IPSC or NMRA more profitable? Neumora Therapeutics has a net margin of 0.00% compared to Century Therapeutics' net margin of -19.10%. Century Therapeutics' return on equity of -10.71% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Century Therapeutics-19.10% -10.71% -5.96% Neumora Therapeutics N/A -84.79%-77.57% SummaryCentury Therapeutics beats Neumora Therapeutics on 9 of the 15 factors compared between the two stocks. Get Century Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPSC vs. The Competition Export to ExcelMetricCentury TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.09M$2.43B$5.56B$9.26BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-2.049.1428.5819.56Price / Sales7.73711.83434.47183.65Price / CashN/A164.3436.0257.93Price / Book0.314.658.165.58Net Income-$126.57M$30.99M$3.24B$257.82M7 Day Performance-5.55%-0.08%-0.64%-0.39%1 Month Performance1.90%7.08%4.93%7.80%1 Year Performance-82.04%-6.56%26.04%12.95% Century Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPSCCentury Therapeutics3.2429 of 5 stars$0.59+2.2%$4.20+610.7%-79.0%$51.09M$6.59M-2.04170News CoverageNMRANeumora Therapeutics2.7245 of 5 stars$1.27-1.6%$7.50+490.6%-87.5%$205.42MN/A-0.79108News CoveragePositive NewsAnalyst ForecastGap UpFDMT4D Molecular Therapeutics2.3659 of 5 stars$4.38+2.3%$29.56+574.8%-84.6%$202.93M$40K-1.38120NLTXNeoleukin TherapeuticsN/A$21.43-2.4%N/A-47.7%$201.40MN/A-6.8990High Trading VolumeEPRXEupraxia Pharmaceuticals2.3899 of 5 stars$5.59+4.3%$11.00+96.8%+99.6%$201.02MN/A-7.3629Gap UpVTYXVentyx Biosciences3.4706 of 5 stars$2.81+2.6%$10.00+255.9%+6.7%$199.96MN/A-1.6130Positive NewsOGIOrganigram Global1.129 of 5 stars$1.48+2.1%N/A-16.4%$198.23M$117.47M14.80860News CoverageSLSSELLAS Life Sciences Group0.354 of 5 stars$1.98+7.6%N/A+74.3%$197.56M$1M-5.2110News CoverageYMABY-mAbs Therapeutics4.1548 of 5 stars$4.36flat$15.60+257.8%-67.5%$197.42M$87.68M-6.81150Positive NewsALMSAlumis3.4535 of 5 stars$3.60+2.3%$22.86+534.9%-69.1%$195.88MN/A0.00N/APositive NewsCTMXCytomX Therapeutics4.1513 of 5 stars$2.39-1.2%$5.33+123.2%+70.2%$192.68M$138.10M4.98170Positive News Related Companies and Tools Related Companies NMRA Alternatives FDMT Alternatives NLTX Alternatives EPRX Alternatives VTYX Alternatives OGI Alternatives SLS Alternatives YMAB Alternatives ALMS Alternatives CTMX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPSC) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IPSC Stock Alerts